Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclopiazonic acid is a fungal secondary metabolite belonging to the class of organic compounds known as 3-alkylindoles. It is produced by certain species of Aspergillus and Penicillium fungi. Cyclopiazonic acid acts as a potent inhibitor of the sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase (SERCA), disrupting calcium homeostasis in cells. It is primarily studied as a mycotoxin due to its presence in contaminated food products and its toxic effects on animals and humans. There are no approved pharmaceutical uses for cyclopiazonic acid; it is considered an experimental compound for research purposes only[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cyclopiazonic acid.